Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol
Cefiderocol is a new siderophore-beta-lactam antibiotic used for the treatment of severe multidrug-resistant infections like sepsis, hospital-acquired and ventilator-associated pneumonia in adults, but there are only single reports on its use in the neonatal population. We describe the successful cefiderocol treatment of a newborn with pneumogenic sepsis due to Stenotrophomonas maltophilia.
Authors
- Susanne Herold (ORCID: https://orcid.org/0000-0001-6343-0911)
- Rahel Schuler (ORCID: https://orcid.org/0000-0003-4629-115X)
- Markus Waitz (ORCID: https://orcid.org/0000-0002-1213-3922)
- Harald Ehrhardt (ORCID: https://orcid.org/0000-0003-4587-1734)
- Moritz Fritzenwanker (ORCID: https://orcid.org/0000-0003-4303-3550)
- Janina Trauth (ORCID: https://orcid.org/0000-0002-1959-7295)
Institutions
- Justus-Liebig-Universität Gießen (DE)
- German Center for Infection Research (DE)
- Cardio-Pulmonary Institute (DE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- Infection
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1007/s15010-024-02404-9
- Citations
- 3
- Primary Topic
- Infections and bacterial resistance
- Type
- article
- Field-Weighted Citation Impact
- 1.85